Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis.

[1]  I. Tannock,et al.  Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial , 2002, The Lancet.

[2]  B N Bundy,et al.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Joos Vandewalle,et al.  Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma , 2001, The Lancet.

[4]  H. V. van Houwelingen,et al.  Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Atkinson,et al.  Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Piccart,et al.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.

[7]  V. Abeler,et al.  Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument , 2000, International Journal of Gynecologic Cancer.

[8]  D. Alberts,et al.  Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. , 1998, British Journal of Cancer.

[9]  D. Gershenson,et al.  Ovarian Cancer: Controversies in Management , 1997 .

[10]  M. Piccart,et al.  Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview. , 1997, European journal of cancer.

[11]  W. Gregory,et al.  A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  P. Reimer,et al.  [High dose chemotherapy with autologous stem cell transplantation]. , 1997, Fortschritte der Medizin.

[13]  D. Alberts,et al.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. , 1996, The New England journal of medicine.

[14]  G. Viale,et al.  The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  D. Cruickshank,et al.  Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Fleuren,et al.  DNA index reflects the biological behavior of ovarian carcinoma stage I-IIa. , 1996, Gynecologic Oncology.

[17]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.

[18]  H. Earl,et al.  Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. , 1995, British Journal of Cancer.

[19]  M. Gore,et al.  The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer , 1995, Anti-cancer drugs.

[20]  M. Bissery,et al.  Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. , 1995, Anti-cancer drugs.

[21]  M. Buyse,et al.  The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1995, The New England journal of medicine.

[22]  J. Thigpen,et al.  Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Gillis,et al.  Management of ovarian cancer: referral to a multidisciplinary team matters. , 1994, British Journal of Cancer.

[24]  F. Ognibene,et al.  Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. , 1994, Journal of the National Cancer Institute.

[25]  M. Christian,et al.  Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  V. Abeler,et al.  Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. , 1993, American journal of obstetrics and gynecology.

[27]  K. Nielsen,et al.  A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). , 1993, Gynecologic oncology.

[28]  C. Runowicz,et al.  Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Rubin,et al.  Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. , 1992, Gynecologic oncology.

[30]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Ettinger,et al.  Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. , 1989 .

[32]  E. Yordan,et al.  A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study , 1986, Cancer.

[33]  T. Lister,et al.  Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Y. Ostchega,et al.  High dose cisplatin and high dose carboplatin in refractory ovarian cancer. , 1985, Cancer treatment reviews.

[35]  P. Vasey.  Survival and longer-term toxicity results of the SCOTROC study : docetaxel-carboplatin (DC) vs. paclitaxelcarboplatin (PC) in epithelial ovarian cancer (EOC) (abstract) , 2002 .

[36]  E. Eisenhauer,et al.  First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin (TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-NCIC CTG Gynaecological Cancer Intergroup phase III trial , 2002 .

[37]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[38]  M. Parmar,et al.  Results of a randomized trial in 923 patients with high-risk early ovarian cancer, comparing adjuvant chemotherapy with no further treatment following surgery , 2001 .

[39]  F M Muggia,et al.  Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Neijt,et al.  First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care? , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  Allen Dg,et al.  A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. , 1995 .

[42]  H. Ngan,et al.  A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group. , 1989, Chemotherapy.